跳至主要内容
临床试验/NCT00853840
NCT00853840已完成4 期

A Randomized, Single-Blinded, Placebo-Controlled Two-Way Crossover Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

ViiV Healthcare1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
18
试验地点
1
主要终点
Standing and Supine Systolic and Diastolic Blood Pressure (BP)

研究概览

简要总结

The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in subjects receiving a single dose of vardenafil.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy male subjects. no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead electrocardiogram and clinical laboratory tests.
  • Body mass index (BMI) of approximately 18 to 30 kg/m2; and a total body weight >50 kg (110 lbs).

排除标准

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
  • Subjects with a supine systolic BP of greater than 140 mm Hg, or a supine diastolic BP of greater than 90 mm Hg, either at Screening or at the predose measurements.

研究组 & 干预措施

1.

Experimental

Maraviroc + Vardenafil

干预措施: Maraviroc (Drug)

1.

Experimental

Maraviroc + Vardenafil

干预措施: Vardenafil (Drug)

2.

Placebo Comparator

Maraviroc + Placebo

干预措施: Maraviroc (Drug)

2.

Placebo Comparator

Maraviroc + Placebo

干预措施: Placebo (Drug)

结局指标

主要结局

Standing and Supine Systolic and Diastolic Blood Pressure (BP)

时间窗: 1.5, 2, 2.5, 3, 4, 6, 8, 12 hours post Vardenafil or Placebo dose

Supine BP was taken after subjects rested for 5 minutes supine. Subjects then sat for 2 minutes and stood for 2 minutes then standing BP taken. Duplicate supine and standing BP measurements were taken per the protocol. The average of the duplicate measurements was calculated prior to data analysis.

次要结局

  • Standing and Supine Pulse Rate(1.5, 2, 2.5, 3, 4, 6, 8, 12 hours post Vardenafil or Placebo dose)
  • Postural Changes in Systolic and Diastolic Blood Pressure(Baseline, 6 and 12 hours post dose on Day 1 from the First Day of each Treatment Leg)
  • Postural Changes in Pulse Rate(Baseline, 6 and 12 hours post dose on Day 1 from the First Day of each Treatment Leg)
  • Number of Subjects With Postural Hypotension(Period 1 and Period 2 (up to 8 days))

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验